

# Angiotensin-converting enzyme 2 (ACE2) levels in relation to clinical outcomes in two large cohorts of patients with atrial fibrillation

European Heart Journal

41, 4037-4046

DOI: [10.1093/eurheartj/ehaa697](https://doi.org/10.1093/eurheartj/ehaa697)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prevention of cardiovascular diseases and dementia: the emerging role of air pollution, socioeconomic factors, e-cigarettes, new biomarkers, proteomics, and genetics. <i>European Heart Journal</i> , 2020, 41, 3969-3972.	1.0	2
2	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4047-4049.	1.0	7
3	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. , 2021, 221, 107750.		34
4	Global Representation of Heart Failure Clinical Trial Leaders and Collaborators: A Systematic Bibliometric Review 2000-2020. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5	Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients. <i>Cells</i> , 2021, 10, 506.	1.8	20
6	Cardiovascular biomarkers in patients with COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 310-319.	0.4	44
7	Predictive value of growth differentiation factor-15 in patients with myocardial infarction. <i>Russian Journal of Cardiology</i> , 2021, 26, 4288.	0.4	3
9	Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum. <i>ACS Infectious Diseases</i> , 2021, 7, 2362-2369.	1.8	32
10	ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1938-1948.	1.2	40
11	Expression of the SARS-CoV-2 receptor ACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. <i>Cardiovascular Diabetology</i> , 2021, 20, 90.	2.7	30
12	<scp>ACE2-based</scp> decoy receptors for <scp>SARS</scp> coronavirus 2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1065-1078.	1.5	23
13	Low plasma angiotensin-converting enzyme 2 level in diabetics increases the risk of severe COVID-19 infection. <i>Aging</i> , 2021, 13, 12301-12307.	1.4	7
14	Circulating Soluble ACE2 and Upstream microRNA Expressions in Serum of Type 2 Diabetes Mellitus Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5263.	1.8	20
15	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	1.8	26
16	Plasma ACE2 species are differentially altered in COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21745.	0.2	18
17	Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart. <i>Cells</i> , 2021, 10, 1708.	1.8	11
18	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. <i>Journal of Medical Virology</i> , 2021, 93, 5908-5916.	2.5	50
19	Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?. <i>Advances in Biological Regulation</i> , 2021, 81, 100820.	1.4	15

#	ARTICLE	IF	CITATIONS
20	Pathophysiology of COVID-19: Everywhere You Look You Will See ACE2!. <i>Frontiers in Medicine</i> , 2021, 8, 694029.	1.2	6
21	GDF15 and Cardiac Cells: Current Concepts and New Insights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8889.	1.8	50
22	Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. <i>Antioxidants</i> , 2021, 10, 1440.	2.2	28
23	Factors Associated with Mortality Among Hospitalized Adults with COVID-19 Pneumonia at a Private Tertiary Hospital in Tanzania: A Retrospective Cohort Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5431-5440.	0.8	7
24	Mass Spectrometry-based Proteomics and Glycoproteomics in COVID-19 Biomarkers Identification: A Mini-review. <i>Journal of Analysis and Testing</i> , 2021, 5, 298-313.	2.5	17
25	Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. <i>American Heart Journal Plus</i> , 2021, 9, 100046.	0.3	6
26	Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	6
27	GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 875-889.	3.1	30
28	Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	3
29	Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. <i>Experimental Gerontology</i> , 2021, 154, 111507.	1.2	52
30	Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients. <i>Reviews in Medical Virology</i> , 2021, 31, 1-12.	3.9	52
31	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. <i>GeroScience</i> , 2021, 43, 2289-2304.	2.1	13
33	Focus on hypertension but also on the "the digital twin"™ and on kidney function and disease. <i>European Heart Journal</i> , 2020, 41, 4531-4534.	1.0	1
34	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
35	The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19. <i>Molecules</i> , 2021, 26, 6945.	1.7	41
36	Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries. <i>Hypertension</i> , 2022, 79, 365-378.	1.3	50
37	Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2022, 115, 8-16.	1.5	54
38	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 814-817.	0.7	2

#	ARTICLE	IF	CITATIONS
39	Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection. <i>Journal of Human Hypertension</i> , 2022, 36, 488-492.	1.0	4
40	Comorbidities Associated with In-Hospital Mortality in Adult Patients with COVID-19 in Lima, Peru: A Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
41	Metainflammation in COVID-19. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1154-1166.	0.6	7
42	Disturbed lipid and amino acid metabolisms in COVID-19 patients. <i>Journal of Molecular Medicine</i> , 2022, 100, 555-568.	1.7	42
43	Prognostic value of growth differentiation factor 15 in COVID-19. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, , 1-3.	0.6	1
44	SARS-CoV-2 interacts with renin-angiotensin system: impact on the central nervous system in elderly patients. <i>GeroScience</i> , 2022, , 1.	2.1	4
45	Coping With Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity. <i>Frontiers in Immunology</i> , 2022, 13, 820350.	2.2	22
46	Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: A systematic review. <i>European Journal of Medical Research</i> , 2022, 27, 26.	0.9	17
47	Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19. <i>Medicina Clínica</i> , 2022, 159, 457-464.	0.3	4
48	Plasma growth differentiation factor 15 in patients with atrial fibrillation. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24373.	0.9	2
49	Genetic Landscape of the ACE2 Coronavirus Receptor. <i>Circulation</i> , 2022, 145, 1398-1411.	1.6	20
50	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. <i>MAbs</i> , 2022, 14, 2057832.	2.6	7
52	The Renin-Angiotensin System as a Component of Biotrauma in Acute Respiratory Distress Syndrome. <i>Frontiers in Physiology</i> , 2021, 12, 806062.	1.3	6
54	Risk factors for impaired pulmonary diffusion function in convalescent COVID-19 patients: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 49, 101473.	3.2	5
55	GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
56	Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. <i>PLoS ONE</i> , 2022, 17, e0271303.	1.1	5
57	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464.	1.0	13
58	Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3

#	ARTICLE	IF	CITATIONS
59	Genome-wide association study of SARS-CoV-2 infection in Chinese population. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 0, , .	1.3	0
60	Serum Angiotensin II as a Biomarker in COVID-19. <i>Biomarkers in Disease</i> , 2022, , 1-24.	0.0	0
61	Serum ACE2 Level is Associated With Severe SARS-CoV-2 Infection: A Cross-Sectional Observational Study. <i>Biomarker Insights</i> , 2022, 17, 117727192211251.	1.0	1
62	COVID-19 and pregnancy: epidemiology, clinical features, maternal and perinatal outcomes. A systematic review. <i>Reproductive Endocrinology</i> , 2022, , 29-37.	0.0	0
63	Hospitalized Patients With COVID-19 Have Higher Plasma Aldosterone-Renin Ratio and Lower ACE Activity Than Controls. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	1
64	Growth differentiation factor 15 as an emerging novel biomarker in SARS-CoV-2 infection. <i>World Journal of Methodology</i> , 2022, 12, 438-447.	1.1	4
65	Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study. <i>Gynecologic Oncology</i> , 2022, 167, 146-151.	0.6	2
66	Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3242-3251.	1.8	3
67	Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 457-464.	0.1	0
68	In silico transcriptional analysis of asymptomatic and severe COVID-19 patients reveals the susceptibility of severe patients to other comorbidities and non-viral pathological conditions. , 2023, 35, 201135.		1
69	Reaching the Final Endgame for Constant Waves of COVID-19. <i>Viruses</i> , 2022, 14, 2637.	1.5	5
70	Circulating angiotensin converting enzyme 2 and COVID-19. <i>World Journal of Clinical Cases</i> , 0, 10, 12470-12483.	0.3	2
71	Atrial fibrillation and stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 35-56.	0.6	13
72	Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. <i>Nature Communications</i> , 2022, 13, .	5.8	8
73	Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
74	Cardio-Oncology and the COVID-19 Pandemic. , 0, , .		0
75	Angiotensin-converting enzyme 2â€™ at the heart of the COVID-19 pandemic. <i>Cell</i> , 2023, 186, 906-922.	13.5	36
76	Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization. <i>Endocrine</i> , 2023, 80, 669-683.	1.1	13

#	ARTICLE	IF	CITATIONS
77	The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction. <i>Kardiologiya</i> , 2023, 63, 40-45.	0.3	1
78	COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5374.	1.8	6
79	Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested case-control study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 403-412.	1.4	3
80	Serum Angiotensin II as a Biomarker in COVID-19. <i>Biomarkers in Disease</i> , 2023, , 917-940.	0.0	0
81	Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). <i>ELife</i> , 0, 12, .	2.8	55
82	Oral Cavity and COVID-19: Clinical Manifestations, Pathology, and Dental Profession. , 2024, , 173-190.		0
83	Circulating proteins to predict COVID-19 severity. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
88	Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	0